Tabula Rasa HealthCare to Provide Care Transition Medication Management for Tandigm Health

MOORESTOWN, N.J. and WEST CONSHOHOCKEN, Pa., June 20, 2017 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare (TRHC), a healthcare technology company optimizing medication safety by deploying new Medication Risk Mitigation digital solutions and novel Medication Decision Support tools, and Tandigm Health, LLC, a value-based healthcare company supporting primary care physicians, announced today that Tandigm has engaged TRHC to assess the medication regimens of high-risk patients who were recently discharged from the hospital, to ensure that regimens are appropriate, effective, safe, taken as intended and have no drug interactions.

Through TRHC’s Care Transitions services, its geriatric certified clinical pharmacists will assess the medication regimen risk by using its Medication Risk Mitigation™ platform, MedWise Advisor®, to consider all medications used prior to a hospitalization and those prescribed upon discharge. Using TRHC’s advanced technology, TRHC pharmacists will work with Tandigm physicians and their patients to streamline and individualize medication regimens.   Outcomes expected to be realized from this initiative include reductions in adverse drug events (ADEs) and decreases in hospital readmission.

“At Tandigm Health, it all starts with healthcare quality,” said Tandigm Chief Medical Officer, Kenneth Goldblum, MD, FACP. “By prioritizing medication safety and effectiveness, we can help our physicians provide the best possible care to their patients as they transfer from a hospital or rehabiltation facilitiy to their homes. We believe TRHC’s unique medication risk mitigation platform and pharmacist follow-up with each patient will help us achieve this goal, and ultimately, reduce readmissions.”

TRHC offers the first prospective clinical solution to Medication Risk Mitigation, which is designed to increase patient safety by reducing the risk for multi-drug adverse drug events and personalizing a patient’s medication regimen. Its innovative technology platform is uniquely equipped to provide comprehensive medication risk management solutions to health plans and provider groups. TRHC’s services will further enhance Tandigm’s ability to provide network physicians with the tools and resources they need in order to deliver proactive, coordinated care.

“TRHC is delighted to partner with Tandigm Health to provide care transition medication risk management,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD. “Medication safety is our highest priority. We are pleased to deploy our medication risk mitigation platform, MedWiseAdvisor®, and clinical pharmacists services, on behalf of Tandigm’s physicians and their thousands of patients.”

The collaboration with Tandigm is an expansion of TRHC’s Care Transitions offering, which it launched earlier this year.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, please visit:

About Tandigm Health

Tandigm Health is dedicated to enhancing the ability of primary care physicians to provide the finest possible care while lowering costs through a more coordinated, proactive model. By providing greater tools and resources to its network of more than 460 physicians, Tandigm puts primary care physicians back at the center of patient care. To learn more about Tandigm’s approach to value-based health care, visit

Micro Interventional Devices, Inc. Wins CRT 2017’s “Top Cardiovascular Innovation Award” for MIA™, Minimally Invasive Annuloplasty Technology

World’s first annuloplasty system for mitral and tricuspid repair incorporating proprietary PolyCor™ and MyoLast™ technologies.

NEWTOWN, Pa., March 2, 2017 /PRNewswire/ — Micro Interventional Devices, Inc™ (MID), is pleased to announce that it is the recipient of the CRT 2017 “Top Cardiovascular Innovation Award” for the company’s MIA™ technology.  The award was presented to Michael Whitman, MID’s Founder, President and CEO, during the 20th annual CRT meeting on Tuesday, February 21st.

“Receiving the 2017 ‘Top Cardiovascular Innovation Award’ at one of the world’s leading interventional cardiology conferences is an honor,” said Michael Whitman.  “The promising early data from our STTAR Study in the EU indicates that our MIA technology is effective in reducing annular dimensions and tricuspid regurgitation.  CRT’s recognition of the encouraging clinical results and the potential for MIA to provide an effective percutaneous solution for the treatment of tricuspid and mitral valve disease is a tremendous accomplishment for our team.”

The MIA technology is designed to reduce annular dimensions and regurgitation during percutaneous transcatheter mitral and tricuspid repair.  The annular reduction is achieved without sutures or other intervention due to the compliant, self-tensioning MIA implant incorporating the company’s proprietary PolyCor™ anchors and MyoLast™ implantable elastomer.

About Micro Interventional Devices, Inc. (MID):

MID is the world leader in percutaneous transcatheter compliant fixation technology addressing unmet needs in structural heart disease.

Company Contact:
Micro Interventional Devices, Inc.
Katherine Whitman
Product Director
215 600 1270

Page 1 of 4412345»102030...Last »